Vaccine Adjuvants: Selection Criteria, Mechanism of Action Associated with Immune Responses and Future Directions. 2023

Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, PR China.

The most effective method to minimize the prevalence of infectious diseases is vaccination. Vaccines enhance immunity and provide protection against different kinds of infections. Subunit vaccines are safe and less toxic, but due to their lower immunogenicity, they need adjuvants to boost the immune system. Adjuvants are small particles/molecules integrated into a vaccine to enhance the immunogenic feedback of antigens. They play a significant role to enhance the potency and efficiency of vaccines. There are several types of adjuvants with different mechanisms of action; therefore, improved knowledge of their immunogenicity will help develop a new generation of adjuvants. Many trials have been designed using different kinds of vaccine adjuvants to examine their safety and efficacy, but in practice, only a few have entered in animal and human clinical trials. However, for the development of safe and effective vaccines, it is important to have adequate knowledge of the side effects and toxicity of different adjuvants. The current review discussed the adjuvants which are available for producing modern vaccines as well as some new classes of adjuvants in clinical trials.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000089582 Adjuvants, Vaccine Substances consisting of different components, e.g. aluminum salts, EMULSIONS such as MF59 and AS03, Toll-like receptor (TLR) agonist or combinations of IMMUNOPOTENTIATORS (QS-21 and MPL in AS01), that helps increase the magnitude of an ADAPTIVE IMMUNE RESPONSE to a VACCINE. Vaccine Adjuvant,Vaccine Adjuvants
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D018579 Patient Selection Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols. Patient Recruitment,Research Subject Recruitment,Selection Criteria,Research Subject Selection,Selection for Treatment,Selection of Research Volunteers,Selection of Subjects,Criteria, Selection,Recruitment, Patient,Recruitment, Research Subject,Recruitments, Research Subject,Research Subject Recruitments,Research Subject Selections,Research Volunteers Selection,Research Volunteers Selections,Selection for Treatments,Selection, Patient,Selection, Research Subject,Selections, Research Subject,Subject Recruitment, Research,Subject Recruitments, Research,Subject Selection, Research,Subject Selections, Research,Subjects Selection,Subjects Selections,Treatment, Selection for,Treatments, Selection for,Volunteers Selection, Research
D022223 Vaccines, Subunit Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides. Subunit Vaccine,Subunit Vaccines,Vaccine, Subunit

Related Publications

Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
May 2009, Vaccine,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
November 2021, Vaccine,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
January 2001, Critical reviews in immunology,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
March 1976, Journal of pharmaceutical sciences,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
February 2003, Vaccine,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
December 2021, Drug delivery,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
January 2013, Frontiers in immunology,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
January 1988, Critical reviews in immunology,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
January 1969, Uspekhi sovremennoi biologii,
Arslan Habib, and Khalid Mahmood Anjum, and Riffat Iqbal, and Ghulam Jaffar, and Zeeshan Ashraf, and Malik ShahZaib Khalid, and Muhammad Usman Taj, and Syeda Wafa Zainab, and Muhammad Umair, and Muhammad Zohaib, and Tabinda Khalid
May 2002, Vaccine,
Copied contents to your clipboard!